Associated Papers
The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications.
Zhang Y et al.
Cancer Medicine, 2026
Improvement of Diagnostics in NSCLC Patients with MET Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations.
Urbanska EM et al.
International Journal of Molecular Sciences, 2025
Successful treatment with sintilimab plus anlotinib for SMARCA4-deficient non-small cell lung cancer withMET exon 14 skipping: a case report.
Zhao H et al.
Nagoya Journal of Medical Science, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
Park J et al.
Targeted Oncology, 2025
The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing.
Liao J et al.
Jto Clinical and Research Reports, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital.
Kim JW et al.
Scientific Reports, 2025
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD et al.
Esmo Open, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Marks JA et al.
Lung Cancer (amsterdam, Netherlands), 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
Li X et al.
Journal of Cancer Research and Clinical Oncology, 2024
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.
Kwon HJ et al.
Cancer Research and Treatment, 2024
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q et al.
Therapeutic Advances in Medical Oncology, 2024
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q et al.
Journal of Cancer, 2024
Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features.
Meng Y et al.
Frontiers in Oncology, 2024
Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.
Ju S et al.
Cancer, 2023
Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
Xia Y et al.
Cancer Letters, 2023
Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non-Small-Cell Lung Cancer.
Sun R et al.
Jco Precision Oncology, 2023
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis.
Talvitie EM et al.
Neoplasia (new York, N.y.), 2022
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.
Tarawneh TS et al.
Cancers, 2022
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E et al.
Genome Medicine, 2022
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Blaquier JB et al.
Drugs in Context, 2022
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib.
Cheng T et al.
Journal of Cancer, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Le X et al.
Jco Precision Oncology, 2021
Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.
Gao B et al.
Frontiers in Medicine, 2021
MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.
Liu XW et al.
Translational Oncology, 2020
Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations.
Reckamp KL et al.
Future Science Oa, 2020
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC.
Cravero P et al.
Jto Clinical and Research Reports, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
Schuler M et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2020
Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients.
Champagnac A et al.
Journal of Thoracic Disease, 2020
Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C et al.
Current Treatment Options in Oncology, 2020
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA et al.
Lung Cancer (amsterdam, Netherlands), 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Drilon A et al.
Nature Medicine, 2020
Non-small cell lung cancer with mesenchymal-epithelial transition gene exon 14 skipping mutation treated with crizotinib.
Katakura S et al.
Respirology Case Reports, 2019
Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens.
Kohsaka S et al.
Cancer Science, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
Ding G et al.
Cancer Biology & Therapy, 2019